Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly
injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.